Observation of the Curative Effect of Mabthera in Combination with the CHOP Regimen in Treating Invasive B-Cell Lymphoma: A Report of 45 Cases

References

1. ↵
   1. Jiang WQ,
   2. Sun XF,
   3. Zhang L, et al.

   Ed. Practical Manual of Medical Oncology Prescription. Guangzhou: Guangdong Science Publishing House 2003; 316-317 (Chinese).
2. ↵
   1. Feugier P,
   2. Van Hoof A,
   3. Sebban C, et al.

   Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. Clin Oncol 2005; 23: 4117-4126.

   OpenUrl
3. ↵
   1. Pfreundschuh M,
   2. Trümper L,
   3. Osterborq A, et al.

   CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Glass B,
   2. Kloess M,
   3. Benter M, et al.

   Dose-escalted CHOP plus etoposide (Mega CHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin’s Lymphoma. Blood 2006; 107: 3058-3064.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Zhou JC.

   Ed. Practical Medical Oncology. Beijing: People’s Medical Publishing House 2003; 29-47 (Chinese).
6. ↵
   1. Jiang WQ,
   2. Zhang XS,
   3. Zhu XF, et al.

   Biotherapeutics of Oncology. Guangzhou: Guangdong Science Publishing House 2006; 13-14.
7. ↵
   1. Lu YQ,
   2. He QH,
   3. Xu J, et al.

   In vitro induction of rituximab on apoptosis of Daudi cells. Zhonghua Xue Ye Xue Za Zhi 2002; 23: 206-207 (Chinese).

   OpenUrl
8. ↵
   1. Maloney DG,
   2. Grillo-lopez A J,
   3. White CA, et al.

   Rituximab anti-CD20 mommclonal antibody therapy in patients with relepsed low-grade non-Hodgkin’s Lymphoma. Blood 1997; 90: 2188-2195.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Jermann M,
   2. Jost LM,
   3. Taverna CH, et al.

   Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15: 511-516.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Kewalramani T,
    2. Zelenetz AD,
    3. Nimer SD, et al.

    Rituximab and ICE assecond-line therapy before autologous stem cell transplantion for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684-3688.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Vose JM,
    2. Link BK,
    3. Grossbard ML, et al.

    Phase 1 study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin’s lymphoma. Clin Oncol 2001; 19: 389-397.

    OpenUrl